FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963963608> ?p ?o ?g. }

• W1963963608 endingPage "1135" @default.
• W1963963608 startingPage "1128" @default.
• W1963963608 abstract "Summary: Purpose: The primary objective of this placebo‐controlled study was to evaluate the safety and tolerability of levetiracetam (LEV) administered intravenously (IV) at higher doses and/or at a faster infusion rate than proposed. The secondary objective was to assess LEV pharmacokinetics. Methods: Single ascending doses of LEV administered by IV infusion (2,000, 3,000, 4,000 mg over 15 min; 1,500, 2,000, 2,500 mg over 5 min) were evaluated in 48 healthy subjects in a randomized, single‐blind, placebo‐controlled study. Results: All randomized subjects completed the study. Adverse events reported after IV administration of LEV (≤4,000 mg infused over 15 min and ≤2,500 mg infused over 5 min) were primarily related to the CNS (dizziness, 52.8%; somnolence, 33.3%; fatigue, 11.1%; headache, 8.3%) and were consistent with the established safety profile for the oral formulation. Safety profiles were similar for each dose level of LEV and for both IV infusion rates, with no clear relation noted between incidence of adverse events and IV dose level or infusion rate. The pharmacokinetics of LEV administered by IV infusion was comparable across all dose groups and infusion rates. Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) μg/ml; area under the plasma concentration–time curve, 1,239 (19.2%) and 585 (9.6%) μg/h/ml; terminal half‐life, 8.0 (14.5%) and 7.0 (12.7%) h. Conclusions: LEV administered by IV infusion at dosages and/or infusion rates higher than those proposed was well tolerated in healthy subjects, and the pharmacokinetic profile was consistent with that for LEV administered orally." @default.
• W1963963608 created "2016-06-24" @default.
• W1963963608 creator A5016899016 @default.
• W1963963608 creator A5022587039 @default.
• W1963963608 creator A5035088033 @default.
• W1963963608 creator A5041694128 @default.
• W1963963608 creator A5042643544 @default.
• W1963963608 creator A5076270839 @default.
• W1963963608 creator A5083455544 @default.
• W1963963608 date "2006-07-01" @default.
• W1963963608 modified "2023-10-17" @default.
• W1963963608 title "Levetiracetam Intravenous Infusion: A Randomized, Placebo-controlled Safety and Pharmacokinetic Study" @default.
• W1963963608 cites W105915516 @default.
• W1963963608 cites W1970167469 @default.
• W1963963608 cites W1972696118 @default.
• W1963963608 cites W1976010985 @default.
• W1963963608 cites W1978723089 @default.
• W1963963608 cites W1979558709 @default.
• W1963963608 cites W1981294852 @default.
• W1963963608 cites W1982281692 @default.
• W1963963608 cites W1982282930 @default.
• W1963963608 cites W1992033758 @default.
• W1963963608 cites W1995302457 @default.
• W1963963608 cites W1996896888 @default.
• W1963963608 cites W2002596642 @default.
• W1963963608 cites W2011785379 @default.
• W1963963608 cites W2025490080 @default.
• W1963963608 cites W2027795477 @default.
• W1963963608 cites W2038141200 @default.
• W1963963608 cites W2038445161 @default.
• W1963963608 cites W2043956784 @default.
• W1963963608 cites W2058896268 @default.
• W1963963608 cites W2083858155 @default.
• W1963963608 cites W2087243332 @default.
• W1963963608 cites W2097906784 @default.
• W1963963608 cites W2119193334 @default.
• W1963963608 cites W2127801604 @default.
• W1963963608 cites W2142051176 @default.
• W1963963608 cites W2155626680 @default.
• W1963963608 cites W2168143783 @default.
• W1963963608 cites W4230618356 @default.
• W1963963608 doi "https://doi.org/10.1111/j.1528-1167.2006.00586.x" @default.
• W1963963608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16886975" @default.
• W1963963608 hasPublicationYear "2006" @default.
• W1963963608 type Work @default.
• W1963963608 sameAs 1963963608 @default.
• W1963963608 citedByCount "168" @default.
• W1963963608 countsByYear W19639636082012 @default.
• W1963963608 countsByYear W19639636082013 @default.
• W1963963608 countsByYear W19639636082014 @default.
• W1963963608 countsByYear W19639636082015 @default.
• W1963963608 countsByYear W19639636082016 @default.
• W1963963608 countsByYear W19639636082017 @default.
• W1963963608 countsByYear W19639636082018 @default.
• W1963963608 countsByYear W19639636082019 @default.
• W1963963608 countsByYear W19639636082020 @default.
• W1963963608 countsByYear W19639636082021 @default.
• W1963963608 countsByYear W19639636082022 @default.
• W1963963608 countsByYear W19639636082023 @default.
• W1963963608 crossrefType "journal-article" @default.
• W1963963608 hasAuthorship W1963963608A5016899016 @default.
• W1963963608 hasAuthorship W1963963608A5022587039 @default.
• W1963963608 hasAuthorship W1963963608A5035088033 @default.
• W1963963608 hasAuthorship W1963963608A5041694128 @default.
• W1963963608 hasAuthorship W1963963608A5042643544 @default.
• W1963963608 hasAuthorship W1963963608A5076270839 @default.
• W1963963608 hasAuthorship W1963963608A5083455544 @default.
• W1963963608 hasConcept C112705442 @default.
• W1963963608 hasConcept C118552586 @default.
• W1963963608 hasConcept C141071460 @default.
• W1963963608 hasConcept C142724271 @default.
• W1963963608 hasConcept C168563851 @default.
• W1963963608 hasConcept C197934379 @default.
• W1963963608 hasConcept C204787440 @default.
• W1963963608 hasConcept C27081682 @default.
• W1963963608 hasConcept C2777332695 @default.
• W1963963608 hasConcept C2778186239 @default.
• W1963963608 hasConcept C2778375690 @default.
• W1963963608 hasConcept C2779034229 @default.
• W1963963608 hasConcept C42219234 @default.
• W1963963608 hasConcept C71924100 @default.
• W1963963608 hasConcept C98274493 @default.
• W1963963608 hasConceptScore W1963963608C112705442 @default.
• W1963963608 hasConceptScore W1963963608C118552586 @default.
• W1963963608 hasConceptScore W1963963608C141071460 @default.
• W1963963608 hasConceptScore W1963963608C142724271 @default.
• W1963963608 hasConceptScore W1963963608C168563851 @default.
• W1963963608 hasConceptScore W1963963608C197934379 @default.
• W1963963608 hasConceptScore W1963963608C204787440 @default.
• W1963963608 hasConceptScore W1963963608C27081682 @default.
• W1963963608 hasConceptScore W1963963608C2777332695 @default.
• W1963963608 hasConceptScore W1963963608C2778186239 @default.
• W1963963608 hasConceptScore W1963963608C2778375690 @default.
• W1963963608 hasConceptScore W1963963608C2779034229 @default.
• W1963963608 hasConceptScore W1963963608C42219234 @default.
• W1963963608 hasConceptScore W1963963608C71924100 @default.
• W1963963608 hasConceptScore W1963963608C98274493 @default.
• W1963963608 hasIssue "7" @default.

• next